Dec82021UncategorizedCategory: UncategorizedBy Charlotte Maddalena8 December 2021 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA Pharma and K.S. KIM sign a license agreement for the distribution of Kigabeq® in the territory of the Russian federationNextNext post:ORPHELIA Pharma raises new money to accelerate its commercial and clinical operationsRelated PostsORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy11 May 2022No title28 April 2022Sondage sur notre communication12 April 2022Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana4 April 2022International Childhood Cancer Day15 February 2022Two new projects supported by our Foundation7 February 2022
ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy11 May 2022
Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana4 April 2022
